The Copenhagen-based cancer immunotherapy company IO Biotech has come to an abrupt end, marking one of the more sobering recent failures in Europe’s mid-cap biotech segment. Founded in 2019, the company had sought to position itself at the forefront of therapeutic cancer vaccines, but a decisive clinical and regulatory setback ultimately proved insurmountable.

The post...

French Generare, founded in 2023, is positioning itself at the intersection of synthetic biology and artificial intelligence by tackling what many in the sector now see as a fundamental bottleneck: the lack of genuinely novel molecular data.

The post

Eli Lilly has agreed to acquire UK-based Centessa Pharmaceuticals in a deal worth up to $7.8 billion, giving the pharma giant a high-profile entry into one of biotech’s most closely watched neuroscience fields: orexin biology. The companies announced a definitive agreement on March 31, 2026.

The post

The Basel region is one of the world’s leading life-science clusters. ­Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the industry continues to grow, the demand for ­scalable laboratory and office environments within this innovation ecosystem is increasing.

<...

Novartis is back on the acquisition trail, agreeing to buy California-based Excellergy for up to $2bn. The antibody Exl-111 is intended to strengthen its allergy pipeline and go beyond the current standard of care. The deal is part of a broader string of acquisitions aimed at systematically expanding the group’s innovation base.

The post